Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Neuropharmacology. 2015 Sep 11;101:46–56. doi: 10.1016/j.neuropharm.2015.09.012

Table 1.

Inhibitory properties of enantiomers of EDDP and EMDP on function of α4β2 and α3β4 nAChR subtypes.

Drug IC50 (μM)
α4β2 nAChRsa α3β4 nAChRsa
(+)-EDDP 1.8 ± 0.6 0.9 ± 0.09
(-)-EDDP 1.4 ± 0.2 0.7 ± 0.06
(+)-EMDP 24 ± 5 7.4 ± 2.1
(-)-EMDP 19 ± 4 7.0 ± 1.2
Mecamylamine 1.0 ± 0.3 3.7 ± 1.2
a

The defined human α4β2 and α3β4 nAChRs are stably expressed in HEK cells designated YXα4β2H1 and YXα3β4H1, respectively. See Materials and Methods for details.

IC50 values were calculated from inhibition curves in which 86Rb+ efflux was stimulated by 100 μM nicotine, as described under Materials and Methods. Mecamylamine, a noncompetitive nAChR antagonist was included for comparison. Data shown are mean ± standard error of three to six independent measurements.